Sun Pharmaceutical Industries Ltd., controlled by Indian billionaire Dilip Shanghvi, rose the most in 14 months after the U.S. approved the company’s generic version of Johnson & Johnson’s cancer drug Doxil.
Emerging-market stocks slid the most in a week, led by energy companies, as China Petroleum & Chemical Corp. sank on a share-sale plan. The rand strengthened after South Africa’s unemployment unexpectedly fell.
AbbVie Inc., the drug unit that split from parent Abbott Laboratories on Jan. 1, sued Indian generic drug maker Sun Pharmaceutical Industries Ltd. for infringing a U.S. patent for Zemplar, used to treat kidney patients.
AbbVie Inc., the drug unit that split from parent Abbott Laboratories on Jan. 1, sued Indian generic drugmaker Sun Pharmaceutical Industries Ltd. for infringing a patent for Zemplar, used to treat kidney patients.
Stada Arzneimittel AG, the German generic-drug maker that spent more than 250 million euros ($331 million) on acquisitions last year, said it expects to draw takeover offers from rivals seeking to expand in Europe.
Sun Pharmaceutical Industries Ltd. is open to acquisition opportunities in Europe and globally as India’s largest drugmaker by value seeks to add products and extend its geographical reach, Chairman Israel Makov said.
Bloomberg Markets’ inaugural list of the world’s richest people showcases the billionaires who pull the levers on the global economy. Their net worth totals $2.7 trillion, about the size of the gross domestic product of France, the fifth-biggest economy on the planet.